On March 11, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the Phase Ib/II clinical study of the company developed bispecific antibody-receptor recombinant protein drug targeting both CD47 and CD20 (Project No.: IMM0306) in combination with lenalidomide (Study No.: IMM0306-003) for the treatment of advanced relapsed/refractory follicular lymphoma (FL) was discussed at the SRC meeting and the Phase II recommended dose was determined, So the project entered Phase II clinical trial officially. This is another milestone achievement in the rapid development of ImmuneOnco.

On February 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that it will present single-agent data of the IMM0306 Phase I and IMM27M Phase I clinical trials and preclinical data of IMM5605 in the form of poster presentations at the 2024 American Association for Cancer Research (AACR 2024) Annual Meeting hold in San Diego, USA, April 5-10.

On February 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, according to the latest quarterly index series released by Hang Seng Indexes Co., Ltd., ImmuneOnco was included in the Hang Seng Composite Index constituent stocks, which will officially take effect on March 4 (Monday) this year.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, Dr. Tian Wenzhi, the company's founder and chairman

On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".